Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

NCT05933863 · clinicaltrials.gov ↗

COMPLETED

Status

168

Enrollment

OTHER

Sponsor class

Conditions

SCLC,Extensive Stage

Interventions

DRUG: PD-(L)1 antibody immunotherapy

Sponsor

Peking University Cancer Hospital & Institute